Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Belgium-based UCB, on behalf of its affiliate UCB Pharma SA, has entered into a definitive settlement agreement with PDL BioPharma, a discoverer of targeted treatments for cancer and immunologic diseases.
Subscribe to our email newsletter
The joint agreement resolves all legal disputes between the two companies, including those relating to UCB’s pegylated humanized antibody fragment, Cimzia (certolizumab pegol), and PDL’s Queen et al. patents.
According to the settlement terms, PDL has provided UCB a covenant not to sue the latter for any royalties regarding UCB’s Cimzia product under the Queen patent portfolio in return for a lump sum payment of $10m and the mutual resolution of other disputes between the two companies.
This includes two pending patent interferences before the US Patent and Trademark Office and a patent opposition in the European Patent Office.
No additional payments will be owed by UCB to PDL under the Queen patents in respect of Cimzia sales.